The invention relates to novel antiviral active components of the general formula 1, pharmaceutical composition, antiviral medicament, method for prophylaxis and treatment of viral diseases, particularly caused by hepatisis C viruses (HCV). In the general formula 1 R1 represents hydrogen, optionally substituted C 1 -C 4 alkyl, C 6 cycloalkyl, aryl, ethoxycarbonyl, nitro group； R2 represents hydrogen； R3 represents N -mono-or N,N -disubstituted 1-methylene-piperidine-3-carboxamide of the general formula 1a or N -mono- or N,N -disubstituted 1-methylene-piperidine-4-carboxamide of the general formula 1b； R4 represents hydrogen, optionally substituted C 1 -C 3 alkyl； or R2 and R3 together with the C-atoms they are attached to form substituted ,3,4,9-tetrahydro-1 H -carbazole of the general formula 1.1, or R2, R3, and R4 together with the atoms they are attached to form substituted azaheterocycles of the eneral formula 1.2； R5 and R6 optionally identical represent hydrogen, optionally substituted C 1 -C 3 alkyl or C 3 -C 6 cydoalkyl, or R5 and R6 together with the N-atom they are attached to form optionally substituted 5- or 6- membered azaheterocyclyl comprising one or two N-atoms and optionally condensed with benzene ring； R7 and R8 represent hydrogen or R7 and R8 together with the C-atom they are attached to form C=O group； R9 represents azaheterocyclyl comprising at least one N-atom, unsubstituted formamide, or phenyl substituted with ethoxycarbonyl or nitro group； R10 represents hydrogen, optionally substituted C 1 -C 3 alkyl, substituted acetyl； n = 1 or 2； solid line accompanied by the dotted line, i.e. ( ), represents single or double C-C bond.本発明は、一般式１の新規の抗ウイルス活性成分、医薬組成物、抗ウイルス薬、ならびにウイルス性疾患、特にＣ型肝炎ウイルス（ＨＣＶ）によって引き起こされる疾患の予防および治療方法に関する。一般式１において、Ｒ１は、水素原子、置換されていてもよいＣ１～Ｃ４アルキル、Ｃ６シクロアルキル、アリール、エトキシカルボニル、ニトロ基であり、Ｒ２は、水素原子であり、Ｒ３は、一般式１ａのＮ－一置換もしくはＮ，Ｎ－二置換１－メチレン－ピペリジン－３－カルボキサミド、または一般式１ｂのＮ－一置換もしくはＮ，Ｎ－二置換１－メチレン－ピペリジン－４－カルボキサミドで
